US 10500229
Targeted disruption of the MHC cell receptor
granted A61KA61K35/00A61K35/17
Quick answer
US patent 10500229 (Targeted disruption of the MHC cell receptor) held by Sangamo Therapeutics, Inc. expires Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Sangamo Therapeutics, Inc.
- Grant date
- Tue Dec 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K35/00, A61K35/17, A61K48/00, A61P